Search results
Decoding the Future of HF — Key Takeaways from 2024
Video Series
Author(s):
Stefan Anker
Added:
2 years ago
HFA 24 - Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE) joins us in this succinct interview to outline the findings of the RELIEVE-HF trial (NCT03499236).RELIEVE-HF was designed to evaluate the safety and effectiveness of the V-Wave inter-atrial shunt system to reduce lung congestion in patients with advanced heart failure. 605 participants with New York Heart Association (NYHA)…
View more
Author(s):
Ambarish Pandey
Added:
7 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more
Author(s):
Ambarish Pandey
Added:
7 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Sean DelaneyIn the landmark FAIR-HF2 randomized clinical trial (NCT03036462)1, intravenous (IV) ferric carboxymaltose did not significantly reduce heart failure (HF) hospitalizations or cardiovascular deaths in patients with heart failure and iron deficiency, despite improving patient-reported quality of life outcomes. Results were presented at ACC.252 and concurrently published in JAMA3…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Sean DelaneyA significant improvement in the use of guideline-directed quadruple medical therapy (QMT) for heart failure with reduced ejection fraction (HFrEF) has been achieved through the IMPLEMENT-HF initiative, according to results published in Circulation: Heart Failure1. Over two years, participating hospitals increased the rate of defect-free QMT at discharge dramatically—from just…
View more
Added:
9 months ago
Source:
Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously…
View more
‘Residual Congestion’ in HF
Author(s):
Aleksandra Gasecka
,
Aleksander Siniarski
Added:
1 year ago
Review Article
Author(s):
Giuseppe Rosano, Lisa Anderson, Antoni Bayés-Genís
Start date:
May 13, 2024
Join us live from the Heart Failure Association (HFA) meeting 2024, for an exclusive discussion between Prof Giuseppe Rosano (St George's Hospital, London, UK), Dr Lisa Anderson (St George's Hospital, London, UK) and Prof Antoni Bayes-Genis (Hospital Germans Trias i Pujol, Barcelona, ES).Our panel will focus on the latest real-world data in the diagnosis and treatment of heart failure (HF) from…
View more